𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer

✍ Scribed by Dorothy S. Lo; Aaron Pollett; Lillian L. Siu; Steve Gallinger; Ronald L. Burkes

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
70 KB
Volume
112
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

Tumor nodules are occasionally found in adjacent mesentery of colorectal cancer specimens and are felt to reflect a worse prognosis. The clinical significance of mesenteric tumor nodules was investigated.

METHODS.

A review of 786 patients with stage III colorectal cancer referred between 1995 and 1999 was undertaken. TNM staging was standardized by considering mesenteric nodules separately and not assigning them to T or N categories. Survival analyses were performed.

RESULTS.

Mesenteric tumor nodules were found in 116 (14.8%) patients: 48 (41.4%) with colon cancer and 68 (58.6%) rectal cancer. Mean age at surgery was 63 years. Adjuvant chemotherapy was given to 84.8% of colon cancer patients. Two (2.9%) rectal cancer patients received neoadjuvant chemoradiation, and 63 (92.6%) received adjuvant therapy (chemotherapy and/or radiation). In the cohort with mesenteric nodules, the median time to progression was 23.1 months, the median 5‐year disease‐free survival was 35%, and the median overall survival (OS) was 47.9 months, with 44% OS at 5 years. In the 19 (16.4%) patients with mesenteric nodules and no lymph nodes the 5‐year OS was 60% (SEER stage II 5‐year survival 82.5%), whereas in 97 patients who were lymph node‐positive the 5‐year OS was 40% (SEER 5‐year survival stage IIIc 44.3%; stage IV 8.1%).

CONCLUSIONS.

In comparison to SEER survival data, the presence of mesenteric nodules appears to worsen the prognosis of any T/N0 disease to that of overall stage III disease. Mesenteric nodules with any T/N+ disease had prognosis similar to that of stage IIIC disease, but the prognosis was better than M1 disease. Cancer 2008. Β© 2007 American Cancer Society.

πŸ“œ SIMILAR VOLUMES

Prognostic impact of hematogenous tumor
Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer
✍ Moritz Koch; Peter Kienle; Dorejd Kastrati; Dalibor Antolovic; Jan Schmidt; Chri πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 240 KB πŸ‘ 1 views

## Abstract Adjuvant chemotherapy is not routinely recommended in patients with colorectal cancer stage UICC II. Some of these patients, however, develop recurrent disease. Therefore, valid prognostic criteria are needed to identify high‐risk patients who might benefit from adjuvant therapy. Dissem

Prognostic significance of serum p53 ant
Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer
✍ GΓ©rard Zalcman; Jean TrΓ©daniel; Beata Schlichtholz; Thierry Urban; Bernard Mille πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 239 KB πŸ‘ 2 views

p53 tumour suppressor gene alterations are one of the most frequent genetic events in lung cancer. A subset of patients with p53 mutation and cancer exhibited circulating serum anti-p53 self-antibodies (p53-Ab). The prevalence of these antibodies in lung cancer is currently being analysed in a multi

Prognostic significance of cyclooxygenas
Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer
✍ Sung-Chul Lim; Tae-Bum Lee; Cheol-Hee Choi; So-Yeon Ryu; Young-Don Min; Kyung-Jo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 257 KB

## Abstract ## Background Cyclooxygenase (COX)‐2 is believed to be an important enzyme related to the pathogenesis of colorectal cancer (CRC). p53 has been reported to be a negative regulator of COX‐2 expression in in vitro studies. The aim of this study was to investigate COX‐2 expression and its